News
Sensorion beschafft rund 31 Millionen Euro (36,5 Millionen US-Dollar) durch eine überzeichnete Privatplatzierung bei US-amerikanischen und europäischen Investoren
Nicht für direkte oder indirekte Freigabe, Veröffentlichung oder Verteilung in bzw. nach den USA, Kanada, Australien oder Japan bestimmt. Diese Pressemitteilung stellt kein Angebot dar und dient
Sensorion beginnt Kapitalerhöhung durch beschleunigtes Bookbuilding-Verfahren
Nicht für direkte oder indirekte Freigabe, Veröffentlichung oder Verteilung in bzw. nach den USA, Kanada, Australien oder Japan bestimmt. Diese Pressemitteilung stellt kein Angebot dar und dient
GenSight Biologics Submits EU Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss Due to Leber Hereditary Optic Neuropathy (LHON)
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for
VALBIOTIS erhält US-amerikanisches und europäisches Patent für TOTUM-070 zur Verminderung von Hypercholesterinämie
Pflichtmitteilung:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Vorbeugung und
VALBIOTIS Receives US and European TOTUM-070 Patent for Reducing Hypercholesterolemia
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating
MND unveils its "Succeed Together 2024" Strategic Plan, driven by its Unique Brand
MND – a French industrial group specialized in ropeway mobility, snowmaking systems, mountain safety, and thrill-making leisure facilities – has unveiled its “Succeed Together 2024” strategic plan
THERANEXUS PRESENTS ITS LATEST SCIENTIFIC NEWS
- New research partnership with the University of Lyon (CERMEP)
- New scientific publications
- Presentation at the European Congress of Neuropsychopharmacology (ECNP)
Lyon, 9 September 2020 –
Median Technologies: Promising Results on the Use of the IBiopsy® Platform in the Context of Measuring the Anti-tumor Immune Response
Regulatory News:
Median Technologies (ALMDT) (Paris:ALMDT), The Imaging Phenomics Company®, today announced the promising results of a first retrospective study on the implementation of the
THERANEXUS : DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Lyon, September 7, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
DIETSWELL : Situation point at the end of July 2020
PRESS RELEASE Paris, August 27, 2020
SITUATION POINT AT THE END OF JULY 2020
· High expected impact of the general contraction in economic and oil activity on 2020 results
·
Median Technologies: Financial Communications Schedule for the Second Half Of 2020
Regulatory News:
Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, announces the publication date for its half year results 2020:
Publication
Date
2020 half year
MND : Mobility: the cable transport specialist MND will build the new HUY ropeway line
The city of Huy in Belgium, with the support of the Walloon Government, has entrusted MND (Euronext Growth - FR0011584549 - ALMND) and its Belgian partners (COP & PORTIER and BPC WALLONIE) with the
Sensorion to present at the Oppenheimer Life Sciences Company Call Series and Virtual World Orphan Drug Congress USA
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
THERANEXUS AND BBDF OBTAIN ORPHAN DRUG DESIGNATION (ODD) AND RARE PEDIATRIC DISEASE DESIGNATION (RPDD) FROM THE FOOD AND DRUG ADMINISTRATION (FDA) FOR BBDF-101 FOR BATTEN DISEASE
- Orphan Drug Designation (ODD) is a status that provides seven years of additional post-approval protection and exemption from filing fees
- Rare Pediatric Disease Designation (RPDD) qualifies the
MND concluded EUR 38 million in new financing from the French State and the Auvergne-Rhône-Alpes Region, as well as from its financial partner Cheyne Capital
- €18 million loan from the French State counter-guaranteed at 50% by the Auvergne-Rhône-Alpes Region
- New €20 million senior loan from Cheyne Capital, financial partner of MND
- Supporting and
THERANEXUS : DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Lyon, August 6, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
First EOSedgeTM installation in the United States
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announces
GECI INTERNATIONAL : 2019-20 FULL-YEAR EARNINGS
During the Board meeting on July 30, 2020, the Directors reviewed and approved the annual financial statements for FY 2019-20, ended March 31, 2020.
Consolidated financials
€m 2019-20 (12
THERANEXUS TO PRESENT THE RESULTS OF THN102 FOR PARKINSON'S DISEASE AT THE 2020 INTERNATIONAL CONGRESS OF PARKINSON'S DISEASE AND MOVEMENT DISORDERS
The MDS Virtual Congress will take place from 12 to 16 September 2020.
Lyon, 30 July 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer
Sensorion appoints five renowned experts to its Scientific Advisory Board
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
VALBIOTIS meldet einen Kassenstand von 10,9 Millionen Euro zum 30. Juni 2020
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen, das sich der wissenschaftlichen Innovation zur Prävention und Bekämpfung von
VALBIOTIS Announces a Cash Position of €10.9M at 30 June 2020
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic
PRISMAFLEX INTERNATIONAL : Total sales Q1 2020-2021: EUR 8.2 million
Activity impacted by the Covid-19 health crisis and economic context
Significant points for 1st quarter:
- Significant impact of Covid-19 pandemic in April and May. Partial recovery begins in June.
GROUPE LDLC : STRONG BUSINESS MOMENTUM IN Q1 2020/2021
- CONSOLIDATED REVENUES UP 43.7% TO €149.1M (UP 23.2% AT CONSTANT CONSOLIDATION SCOPE)
- STRONG BTOC REVENUE GROWTH: UP 77.3% to €115.7M (UP 44.7% AT CONSTANT CONSOLIDATION SCOPE)
- 2020/2021 TARGETS
EOS Imaging Reports Strong Revenue Growth for Half Year 2020
Regulatory News:
EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - PEA-PME eligible), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and